Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA, PLW

FDA approves Orthogen's IDE

Orthogen to launch pivotal trial of novel therapy for knee osteoarthritis

DÜSSELDORF, Germany, Jan. 18, 2023 /PRNewswire/ -- Orthogen AG, a leader in molecular medicine, announces U.S. Food and Drug Administration (FDA) approval of an Investigational Device Exemption (IDE) for the company's proprietary technology, Orthogen® Device (OD). This approval allows the company to start a pivotal trial in the U.S., using OD for treatment of patients with knee osteoarthritis, stages II-IV.

The pivotal trial will compare improvements in pain and function using standalone glucocorticoid injections (the current standard of care) with Orthogen's patented therapy of concomitant autologous conditioned serum (ACS) and glucocorticoids in patients with knee osteoarthritis, stages II-IV.

ACS is obtained using each patient's own blood, drawn at site of care. The OD's closed system design enables standardized blood taking, extended extracorporeal coagulation, and serum separation to obtain ACS, which is then injected into the patient's knee on the same day.

OD-obtained ACS is intended as add-on therapy for long-term pain reduction and functional improvement in knee osteoarthritis patients, stage II-IV, receiving an intra-articular injection of FDA-approved glucocorticoids in accordance with FDA's approved labeling.

More than 32.5 million Americans suffer from osteoarthritis, according to the Centers for Disease Control and Prevention (CDC).  The burden on the US economy is an estimated $150 billion annually in lost wages and medical bills. By 2050, the number of US patients diagnosed with osteoarthritis is projected to double.

Peter Wehling, MD, PhD, Chief Executive Officer of Orthogen AG, said "This IDE approval is a significant step towards bringing a much-needed solution to this urgent, worldwide problem of osteoarthritis. We are now looking for a development and commercialization partner to support PMA approval and a subsequent full-fledged launch including wide reimbursement coverage enabling access for a large patient group."

About Orthogen AG

Orthogen AG ( www.orthogen.com ), founded in 1993 and located in Düsseldorf, Germany is pioneering the field of molecular and autologous medicine with its groundbreaking technologies. The company has created a strong and valuable patent portfolio with several issued patents and patents pending. Orthogen AG's executive management team, Scientific Advisory Board and Board of Directors are seasoned professionals and key opinion leaders in the areas of biology, healthcare and medical device product development.

Public & Investor relations contact
Benjamin Wehling
+49 173 5219914
[email protected]

These press releases may also interest you

at 18:35
Klear.ai, a pioneer in native AI insurance software solutions for claims, risk and analytic solutions, today announced the successful acquisition of the Inform business (Inform), of Cloud software Group, Inc. (Cloud Software Group). Inform is a Risk...

at 18:27
EK®, the leading manufacturer of premium-grade liquid cooling solutions, will be present at the PAX EAST 2023 event in Boston, March 23-26, at Booth #16055. The EK team, along with EK's partners ? TeamGroup, BeQuiet!, MountainGG, and AMD will present...

at 18:15
The "Africa & Middle East Prepaid Card and Digital Wallet Business and Investment Opportunities Databook - Market Size and Forecast, Consumer Attitude & Behaviour, Retail Spend - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...

at 18:00
Diebold Nixdorf, Incorporated (the "Company") today announced it has extended its previously announced public exchange offer (the "Exchange Offer") with respect to the Company's outstanding 8.50% Senior Notes due 2024 (144A CUSIP: 253651AA1; REG S...

at 17:44
Media are invited to visit NASA's simulated Mars habitat on Tuesday, April 11, at the agency's Johnson Space Center in Houston. This summer, four volunteers will begin a yearlong Mars mission in the ground-based habitat, helping NASA prepare for...

at 17:30
Cybeats Technologies Corp. ("Cybeats'' or the "Company") is pleased to announce the commencement of a trial evaluation with one of the top-3 largest software companies by total revenue, for Cybeats SBOM Studio.1...

News published on 18 january 2023 at 07:00 and distributed by: